BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

957 related articles for article (PubMed ID: 26763251)

  • 21. CXCL13-producing CD4+ T cells accumulate in the early phase of tertiary lymphoid structures in ovarian cancer.
    Ukita M; Hamanishi J; Yoshitomi H; Yamanoi K; Takamatsu S; Ueda A; Suzuki H; Hosoe Y; Furutake Y; Taki M; Abiko K; Yamaguchi K; Nakai H; Baba T; Matsumura N; Yoshizawa A; Ueno H; Mandai M
    JCI Insight; 2022 Jun; 7(12):. PubMed ID: 35552285
    [TBL] [Abstract][Full Text] [Related]  

  • 22. T-cell recognition of ovarian cancer.
    Peoples GE; Schoof DD; Andrews JV; Goedegebuure PS; Eberlein TJ
    Surgery; 1993 Aug; 114(2):227-34. PubMed ID: 8342128
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antigen Specificity and Clinical Significance of IgG and IgA Autoantibodies Produced
    Garaud S; Zayakin P; Buisseret L; Rulle U; Silina K; de Wind A; Van den Eyden G; Larsimont D; Willard-Gallo K; Linē A
    Front Immunol; 2018; 9():2660. PubMed ID: 30515157
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.
    Morales-Kastresana A; Sanmamed MF; Rodriguez I; Palazon A; Martinez-Forero I; Labiano S; Hervas-Stubbs S; Sangro B; Ochoa C; Rouzaut A; Azpilikueta A; Bolaños E; Jure-Kunkel M; Gütgemann I; Melero I
    Clin Cancer Res; 2013 Nov; 19(22):6151-62. PubMed ID: 24030703
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phenotypic and functional analysis of tumor-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and peripheral blood lymphocytes in patients with advanced ovarian cancer.
    Santin AD; Hermonat PL; Ravaggi A; Bellone S; Roman JJ; Smith CV; Pecorelli S; Radominska-Pandya A; Cannon MJ; Parham GP
    Gynecol Obstet Invest; 2001; 51(4):254-61. PubMed ID: 11408737
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New insights into tumor immunity revealed by the unique genetic and genomic aspects of ovarian cancer.
    Nelson BH
    Curr Opin Immunol; 2015 Apr; 33():93-100. PubMed ID: 25710852
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer.
    Milne K; Barnes RO; Girardin A; Mawer MA; Nesslinger NJ; Ng A; Nielsen JS; Sahota R; Tran E; Webb JR; Wong MQ; Wick DA; Wray A; McMurtrie E; Köbel M; Kalloger SE; Gilks CB; Watson PH; Nelson BH
    PLoS One; 2008; 3(10):e3409. PubMed ID: 18923710
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer.
    Yang M; Lu J; Zhang G; Wang Y; He M; Xu Q; Xu C; Liu H
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33452206
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bispecific antibodies enhance tumor-infiltrating T cell cytotoxicity against autologous HER-2-expressing high-grade ovarian tumors.
    Oberg HH; Janitschke L; Sulaj V; Weimer J; Gonnermann D; Hedemann N; Arnold N; Kabelitz D; Peipp M; Bauerschlag D; Wesch D
    J Leukoc Biol; 2020 Jun; 107(6):1081-1095. PubMed ID: 31833593
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systematic evaluation of multiple immune markers reveals prognostic factors in ovarian cancer.
    Santoiemma PP; Reyes C; Wang LP; McLane MW; Feldman MD; Tanyi JL; Powell DJ
    Gynecol Oncol; 2016 Oct; 143(1):120-127. PubMed ID: 27470997
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictive Value of Tertiary Lymphoid Structures Assessed by High Endothelial Venule Counts in the Neoadjuvant Setting of Triple-Negative Breast Cancer.
    Song IH; Heo SH; Bang WS; Park HS; Park IA; Kim YA; Park SY; Roh J; Gong G; Lee HJ
    Cancer Res Treat; 2017 Apr; 49(2):399-407. PubMed ID: 27488875
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potential role of tumor-infiltrating T-, B-lymphocytes, tumor-associated macrophages and IgA-secreting plasma cells in long-term survival in the rectal adenocarcinoma patients.
    Zinovkin DA; Kose SY; Nadyrov EA; Achinovich SL; Los' DM; Gavrilenko TE; Gavrilenko DI; Yuzugulen J; Pranjol MZI
    Life Sci; 2021 Dec; 286():120052. PubMed ID: 34656554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma.
    Siliņa K; Soltermann A; Attar FM; Casanova R; Uckeley ZM; Thut H; Wandres M; Isajevs S; Cheng P; Curioni-Fontecedro A; Foukas P; Levesque MP; Moch H; Linē A; van den Broek M
    Cancer Res; 2018 Mar; 78(5):1308-1320. PubMed ID: 29279354
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
    Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
    Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470
    [TBL] [Abstract][Full Text] [Related]  

  • 35. T cell receptor V beta 2 and V beta 6 mediate tumor-specific cytotoxicity by tumor-infiltrating lymphocytes in ovarian cancer.
    Peoples GE; Davey MP; Goedegebuure PS; Schoof DD; Eberlein TJ
    J Immunol; 1993 Nov; 151(10):5472-80. PubMed ID: 8228239
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancer.
    Banville AC; Wouters MCA; Oberg AL; Goergen KM; Maurer MJ; Milne K; Ashkani J; Field E; Ghesquiere C; Jones SJM; Block MS; Nelson BH
    Gynecol Oncol; 2021 Feb; 160(2):520-529. PubMed ID: 33342620
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
    Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
    Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Do tumor-infiltrating lymphocytes really indicate favorable prognosis in epithelial ovarian cancer?
    Yildirim N; Akman L; Acar K; Demir S; Ozkan S; Alan N; Zekioglu O; Terek MC; Ozdemir N; Ozsaran A
    Eur J Obstet Gynecol Reprod Biol; 2017 Aug; 215():55-61. PubMed ID: 28601728
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma.
    Tomsová M; Melichar B; Sedláková I; Steiner I
    Gynecol Oncol; 2008 Feb; 108(2):415-20. PubMed ID: 18037158
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies.
    Wong JT; Pinto CE; Gifford JD; Kurnick JT; Kradin RL
    J Immunol; 1989 Nov; 143(10):3404-11. PubMed ID: 2509557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 48.